Rossari Biotech Ltd

- The company is planning CAPEX investments, with a total spend of about Rs.180 crore for expansions at Dahej (Unitop and Rossari facilities). - For financing the CAPEX, the management intends to raise debt with an estimated debt-to-internal accrual ratio of approximately 75:25. - As of the call, discussions with banks regarding the debt are ongoing, and specific details on the debt quantum and interest costs are yet to be finalized. - Currently, no plans or discussions on equity fundraising or acquisitions were mentioned. - The CAPEX and related financing are expected to contribute to growth, with commissioning targeted by Q3 FY25. No explicit mention of any immediate or future equity fundraising was disclosed in the call.

- Rossari is undertaking a total CAPEX of Rs.180 crore, primarily for the expansion of the Dahej facility and ethoxylation capacity at Unitop. - The expansion aims to foray into new products related to HPPC segments like agrochemicals, home and personal care, oil and gas, and pharmaceuticals. - CAPEX spending is phased, with significant expenditures expected in the current and next quarters and completion targeted by Q3 FY25. - An additional CAPEX of Rs.50 crore is earmarked for new equipment related to specialty textile products and pilot batches. - The company is increasing ethoxylation capacity more than twofold due to robust surfactant demand. - Plans include investment in biosurfactant capacity expansion (currently 3 tons/month, aimed to increase tenfold). - Debt-to-internal accrual ratio for financing CAPEX is expected to be roughly 75:25. - No acquisitions are currently planned in Textiles or Animal Health Nutrition segments. Overall, Rossari focuses on organic expansions across core chemistries with phased CAPEX to support growth.

- Company targets mid-teen (~15%) top-line growth for the next financial year, excluding CAPEX impact. - Export turnover expected to grow at 12%-14%, higher than domestic turnover growth forecasted around 10%. - HPPC division driving robust growth, with volume increases of 30%-35%+ Y-o-Y in recent quarters. - Institutional Chemicals, Specialty Surfactants (non-agro), and Phenoxy Series see fastest growth within HPPC. - New product launches and capacity expansions (notably ethoxylation at Dahej) aim to boost volumes. - CAPEX projects (Rs.180 crore at Dahej) expected to complete by Q3 FY25 leading to significant future sales. - Textile specialty division currently facing soft demand but expected to recover with domestic/export uptick. - Biosurfactants production targeted to expand 10x from current 3 tons/month. - Overall, management confident of sustained volume and revenue growth supported by R&D and capacity expansions.

- Rossari Biotech expects mid-teen revenue growth (~15%) for the next financial year. - Export turnover is forecasted to grow faster (12%-14%) than domestic turnover (10%). - EBITDA margins are projected to maintain around 13.67%-14.12% in the near term. - Absolute EBITDA growth is expected to be in line with top-line growth (~mid-teens). - Profitability improvement is anticipated due to better capacity utilization and growth initiatives. - Long-term growth aims at sustained revenue CAGR of over 25% between FY21 and FY24. - Management plans continued introduction of new products within existing chemistries to drive future growth. - Expansion CAPEX of Rs.180 crore at Dahej facility (ethoxylation capacity doubling) to support growth by FY25. - No indication of surpassing prior FY24 revenue guidance of 10%-12%, management remains conservative on guidance.

The transcript provided does not explicitly mention details about the current or expected order book or pending orders for Rossari Biotech Limited. The discussion mainly focuses on capacity utilization, product launches, financial performance, and future growth initiatives. No specific data on order backlog or pending orders is disclosed in the transcript. For detailed information on the order book or pending orders, it is suggested to contact the company directly or refer to their official disclosures or investor presentations.